keyword
MENU ▼
Read by QxMD icon Read
search

Hairy cell leukemia

keyword
https://www.readbyqxmd.com/read/27910030/recurrent-cytogenetic-abnormalities-in-non-hodgkin-s-lymphoma-and-chronic-lymphocytic-leukemia
#1
Edmond S K Ma
Characteristic chromosomal translocations are found to be associated with subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph node or other tissue is seldom submitted for conventional cytogenetics study, alternative approaches for translocation detection are polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH)...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27903528/consensus-guidelines-for-the-diagnosis-and-management-of-patients-with-classic-hairy-cell-leukemia
#2
Michael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, Versha Banerji, Jacqueline Barrientos, James S Blachly, Timothy G Call, Daniel Catovsky, Claire Dearden, Judit Demeter, Monica Else, Francesco Forconi, Alessandro Gozzetti, Anthony D Ho, James B Johnston, Jeffrey Jones, Gunnar Juliusson, Eric Kraut, Robert J Kreitman, Loree Larratt, Francesco Lauria, Gerard Lozanski, Emili Montserrat, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme R Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Alan Saven, John F Seymour, Tamar Tadmor, Martin S Tallman, Constantine Tam, Enrico Tiacci, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Zinzani, Brunangelo Falini
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. As more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease...
November 30, 2016: Blood
https://www.readbyqxmd.com/read/27803415/toxoplasmic-encephalitis-with-untreated-hairy-cell-leukemia-variant
#3
Taichi Ikebe, Hitohiro Sasaki, Hiroyuki Takata, Yasuhiko Miyazaki, Eiichi Ohtsuka, Yoshio Saburi, Masao Ogata, Kuniaki Shirao
Toxoplasmic encephalitis is a rare infectious complication in patients with hematological malignancy except for allogeneic hematopoietic stem cell transplantation (HSCT). We herein report a case of possible toxoplasmic encephalitis with untreated hairy cell leukemia variant. Magnetic resonance imaging showed multiple nodules with surrounding edema in the entire cerebrum. A polymerase chain reaction analysis for Toxoplasma gondii was negative. Her signs and symptoms fully recovered by empirical therapy with sulfadiazine and pyrimethamine...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27790140/the-droplet-digital-pcr-a-new-valid-molecular-approach-for-the-assessment-of-b-raf-v600e-mutation-in-hairy-cell-leukemia
#4
Francesca Guerrini, Matteo Paolicchi, Francesco Ghio, Elena Ciabatti, Susanna Grassi, Serena Salehzadeh, Giacomo Ercolano, Maria R Metelli, Marzia Del Re, Lorenzo Iovino, Iacopo Petrini, Giovanni Carulli, Nadia Cecconi, Martina Rousseau, Giulia Cervetti, Sara Galimberti
Hairy cell leukemia (HCL) is a chronic lymphoproliferative B-cell disorder where the B-RAF V600E mutation has been recently detected, as reported for solid neoplasias but not for other B-cell lymphomas. The digital droplet PCR (dd-PCR) is a molecular technique that, without standard references, is able to accurately quantitate DNA mutations. ddPCR could be an useful instrument for the detection of the B-RAF V600E mutation in HCL, where the minimal residual disease monitoring is fundamental for planning a patients-targeted treatment in the era of new anti-CD20 and anti-RAF compounds...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27733095/ibrutinib-for-relapsed-refractory-hairy-cell-leukemia-variant
#5
Jan-Paul Bohn, David Wanner, Michael Steurer
No abstract text is available yet for this article.
October 12, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27727469/refractory-hairy-cell-leukemia-variant
#6
Zhihong Hu, Yi Sun, Wei Wang, L Jeffrey Medeiros, Rashmi Kanagal-Shamanna
No abstract text is available yet for this article.
October 11, 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27725920/flow-cytometric-analysis-four-year-experience-in-a-tertiary-care-centre-of-pakistan
#7
Imran N Ahmad, Salman Assad, Muhammad Rahman, Haider Ghazanfar
PURPOSE:   This study summarizes a four-year experience from the analysis of hematolymphoid malignancies in Pakistani population using a database of six-colored flow cytometry. METHODS: A cross-sectional survey of 323 specimens of hematolymphoid malignancies using six-colored flow cytometry (FC) was carried out in Shifa International Hospital, Islamabad, Pakistan from June 2012 to June 2016. The criterion for specimen adequacy was that the cases have abnormal populations by FC, and the specimen age (time from biopsy to being examined by the six-color FC tube) of three days or less was to be included in the study...
September 1, 2016: Curēus
https://www.readbyqxmd.com/read/27721294/primary-plasma-cell-leukemia-a-report-of-two-cases-of-a-rare-and-aggressive-variant-of-plasma-cell-myeloma-with-the-review-of-literature
#8
Prithal Gangadhar, Zulfikar Ahmed, Muktha R Pai, I Sandhya
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma accounting for 2-3% of all plasma cell dyscrasias characterized by the presence of circulating plasma cells. The diagnosis is based on the % (≥20%) and absolute number (≥2x10 9 /L) of plasma cells in the peripheral blood. The incidence of primary PCL (pPCL) is very rare and reported to occur in <1 in a million. It is classified as either pPCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. pPCL is a distinct clinicopathological entity with different cytogenetic and molecular findings...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27685932/composite-hairy-cell-leukemia-and-chronic-lymphocytic-leukemia
#9
Alexandra Papoudou-Bai, Amalia Vassou, Georgios Vartholomatos, Evangelos Briasoulis, Panagiotis Kanavaros
No abstract text is available yet for this article.
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/27648170/unusual-presentation-of-erdheim-chester-disease-in-a-child-with-acute-lymphoblastic-leukemia
#10
Archana George Vallonthaiel, Asit Ranjan Mridha, Shivanand Gamanagatti, Manisha Jana, Mehar Chand Sharma, Shah Alam Khan, Sameer Bakhshi
Erdheim-Chester disease (ECD) is an uncommon, non-familial, non-Langerhans cell histiocytosis, which involves skeletal system and soft tissue usually in middle aged and elderly patients. The characteristic radiologic features include bilateral, symmetric cortical osteosclerosis of the diaphyseal and metaphyseal parts of the long bones, or bilateral symmetrically abnormal intense (99m)Technetium labelling of the metaphyseal-diaphyseal region of the long bones, and computed tomography scan findings of "coated aorta" or "hairy kidneys"...
August 28, 2016: World Journal of Radiology
https://www.readbyqxmd.com/read/27618563/2016-us-lymphoid-malignancy-statistics-by-world-health-organization-subtypes
#11
Lauren R Teras, Carol E DeSantis, James R Cerhan, Lindsay M Morton, Ahmedin Jemal, Christopher R Flowers
Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected...
September 12, 2016: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/27582569/clinical-impact-of-recurrently-mutated-genes-on-lymphoma-diagnostics-state-of-the-art-and-beyond
#12
REVIEW
Richard Rosenquist, Andreas Rosenwald, Ming-Qing Du, Gianluca Gaidano, Patricia Groenen, Andrew Wotherspoon, Paolo Ghia, Philippe Gaulard, Elias Campo, Kostas Stamatopoulos
Similar to the inherent clinical heterogeneity of most, if not all, lymphoma entities, the genetic landscape of these tumors is markedly complex in the majority of cases, with a rapidly growing list of recurrently mutated genes discovered in recent years by next-generation sequencing technology. Whilst a few genes have been implied to have diagnostic, prognostic and even predictive impact, most gene mutations still require rigorous validation in larger, preferably prospective patient series, to scrutinize their potential role in lymphoma diagnostics and patient management...
September 2016: Haematologica
https://www.readbyqxmd.com/read/27581226/selective-spleen-embolization-of-splenomegaly-to-improve-thrombocytopenia-facilitating-open-aortic-aneurysm-repair-a-staged-approach
#13
Dimitrios Maras, Nikolaos Kontopodis, Athansios Dedes, Antonios Tsanis, Ioannis Mazarakis, Christos Gekas, Christos V Ioannou
We present an 82-year-old man with a history of hairy cell leukemia, having an 11-cm abdominal aortic aneurysm, who also had severe thrombocytopenia (about 20 000 platelets/μL) and splenomegaly at presentation. The patient had unfavorable anatomy for endovascular aneurysm repair, and therefore, an open procedure was planned. To reduce risk for perioperative bleeding and optimize patient preoperative status, a staged approach was employed. Initially, several sessions of embolization of 2 splenic artery branches were performed with the intent to decrease spleen size and to increase platelet count thus decreasing the perioperative bleeding risk...
August 2016: Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/27573126/hidradenitis-suppurativa-and-the-association-with-hematological-malignancies-a-review-of-2-cases
#14
Bahman Sotoodian, Mariam Abbas, Alain Brassard
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting skin sites with a high density of apocrine glands. HS commonly presents after puberty, with most patients diagnosed in the second decade of their life. Several studies have investigated smoking, obesity, hypertension, diabetes, and dyslipidemia as possible underlying risk factors for HS. However, we encountered 2 patients with a long-standing history of untreated leukemia who developed late-onset HS...
August 29, 2016: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/27554081/braf-v600e-mutation-in-hairy-cell-leukemia-from-bench-to-bedside
#15
Brunangelo Falini, Maria Paola Martelli, Enrico Tiacci
Hairy cell leukemia (HCL) is a distinct clinicopathological entity whose underlying genetic lesion has remained a mystery for over half a century. The BRAF V600E mutation is now recognized as the causal genetic event of HCL because it is somatic, present in the entire tumor clone, detectable in almost all cases at diagnosis (encompassing the whole disease spectrum), and stable at relapse. BRAF V600E leads to the constitutive activation of the RAF-MEK-extracellular signal-regulated kinase (ERK) signaling pathway which represents the key event in the molecular pathogenesis of HCL...
October 13, 2016: Blood
https://www.readbyqxmd.com/read/27499139/human-memory-b-cells
#16
REVIEW
M Seifert, R Küppers
A key feature of the adaptive immune system is the generation of memory B and T cells and long-lived plasma cells, providing protective immunity against recurring infectious agents. Memory B cells are generated in germinal center (GC) reactions in the course of T cell-dependent immune responses and are distinguished from naive B cells by an increased lifespan, faster and stronger response to stimulation and expression of somatically mutated and affinity matured immunoglobulin (Ig) genes. Approximately 40% of human B cells in adults are memory B cells, and several subsets were identified...
August 26, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27462230/a-unique-hairy-cell-leukemia-variant
#17
Charles Jian, Cyrus C Hsia
A 65-year-old woman presented with easy bruising, left upper quadrant pain, decreased appetite, and weight loss. She had splenomegaly and lymphocytosis (lymphocyte count of 11.6 × 10(9)/l), with remarkably abnormal appearing morphology. Her hemoglobin and platelet counts were normal. Peripheral blood flow cytometry revealed a monoclonal B-cell population expressing CD11c, CD25, CD19, CD20, and CD103. An initial diagnosis of hairy cell leukemia (HCL) was made, and the patient was treated with a standard 5-day course of cladribine...
May 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27429657/long-term-treatment-of-hairy-cell-leukemia-with-interferon-%C3%AE-still-a%C3%A2-viable-therapeutic-option
#18
Jan-Paul Bohn, Guenther Gastl, Michael Steurer
Classic hairy cell leukemia (HCL) is a rare indolent B‑cell-lymphoproliferative disorder, first described as a distinct disease entity in 1958. After more than two decades without effective chemotherapeutic options and a dismal prognosis of less than 5 years, only the introduction of interferon‑α (IFN‑α) allowed for response rates between 80-90 % and survival improvement. Nowadays, however, patients are rarely treated with IFN-α as purine analogues were found to be highly effective in HCL facilitating a near normal life span in most cases...
2016: Memo
https://www.readbyqxmd.com/read/27334277/nanocarriers-for-spleen-targeting-anatomo-physiological-considerations-formulation-strategies-and-therapeutic-potential
#19
REVIEW
Anil B Jindal
There are several clinical advantages of spleen targeting of nanocarriers. For example, enhanced splenic concentration of active agents could provide therapeutic benefits in spleen resident infections and hematological disorders including malaria, hairy cell leukemia, idiopathic thrombocytopenic purpura, and autoimmune hemolytic anemia. Furthermore, spleen delivery of immunosuppressant agents using splenotropic carriers may reduce the chances of allograft rejection in organ transplantation. Enhanced concentration of radiopharmaceuticals in the spleen may improve visualization of the organ, which could provide benefit in the diagnosis of splenic disorders...
October 2016: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/27282942/braf-inhibitor-targeted-therapy-in-hairy-cell-leukemia
#20
Michael R Grever
No abstract text is available yet for this article.
June 9, 2016: Blood
keyword
keyword
83244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"